Efficacy Of Bacterial Lysate In Children With Allergic Rhinitis
Ключевые слова
абстрактный
Описание
Seasonal allergic rhinitis (SAR) is caused by the allergens of wind-pollinated plants, and in Poland mainly by grass pollen allergens. During the grass pollen season, patients may suffer from fatigue, weakness, lack of fitness, difficulty in sleeping and reduced performance at school. In people allergic to the above-mentioned pollen, the disease significantly reduces the quality of life and requires intensive treatment in the pollen period.
Due to the high incidence of allergic rhinitis, the negative impact of the disease on the quality of life, and incomplete effectiveness of previously available therapeutic methods, new methods of treatment are being developed. Recent research highlights the immunoregulatory potential of bacterial lysates, indicating the possibility of their future use in the prevention and treatment of allergic diseases, including atopic dermatitis, allergic rhinitis, and asthma. However, so far no randomized, double-blind, placebo-controlled, study with bacterial lysate in children's SAR therapy has been conducted.
The main aim of this study was to evaluate the clinical course of the pollen allergic rhinitis, caused by grass pollen allergens in children during the grass pollen season, treated with polyvalent mechanical bacterial lysate (PMBL). The approval of the Bioethics Committee at the Medical University in Lublin was obtained for the study.
Seventy children with SAR were enrolled to this study and were randomly assigned to the PMBL group (n=35) and placebo group (n=35). Three visits took place as part of the study: at the beginning of the grass pollen season, at the peak, and at the end of the season. The time frame of the grass pollen season for south-eastern Poland was determined using the "95%" method on the basis of measurements of grass pollen concentration in the atmospheric air, which were obtained from the Environmental Allergy Research Centre in Warsaw.
Nasal and ocular SAR symptoms were recorded by parents of children in the daily patient diary according to the standard scoring systems (TNSS, total nasal symptom score and TOSS, total ocular symptom score), and their intensity was also evaluated during three visits using VAS (visual analogue scale). At each visit, peak nasal inspiratory flow (PNIF) was also measured.
In order to determine the mechanism responsible for the possible effects of PMBL, samples were taken from patients for additional testing: nasal smears for the presence of eosinophils and nasal lavage fluids for the presence of allergen-specific IgE (asIgE) against timothy grass pollen allergens.
Даты
| Последняя проверка: | 01/31/2020 |
| Первый отправленный: | 02/09/2020 |
| Предполагаемая регистрация отправлена: | 02/11/2020 |
| Первое сообщение: | 02/16/2020 |
| Последнее обновление отправлено: | 02/11/2020 |
| Последнее обновление опубликовано: | 02/16/2020 |
| Фактическая дата начала исследования: | 04/21/2018 |
| Предполагаемая дата завершения начальной школы: | 07/19/2018 |
| Предполагаемая дата завершения исследования: | 08/11/2018 |
Состояние или болезнь
Вмешательство / лечение
Drug: Ismigen
Drug: Placebo
Фаза
Группы рук
| Рука | Вмешательство / лечение |
|---|---|
| Experimental: Ismigen Treatment over 3 successive months with one daily tablet over 10 days followed by 20 days of rest. | Drug: Ismigen Sublingual tablets containing 7 mg of bacterial lysate from the following bacteria: Staphylococcus aureus, Haemophilus influenzae serotype B, Klebsiella pneumoniae, Klebsiella ozaenae, Neiserria catarrhalis, Streptococcus viridans, Streptococcus pyogenes, Streptococcus pneumoniae (6 strains: TY1/EQ11, TY2/EQ22, TY3/EQ14, TY5/EQ15, TY8/EQ23, TY47/EQ24) - sublingual use 1 tablet per day over 10 days for 3 successive months. |
| Placebo Comparator: Placebo Treatment over 3 successive months with one daily tablet over 10 days followed by 20 days of rest. | Drug: Placebo Matched tablets without any active substance. |
Критерии приемлемости
| Возраст, имеющий право на обучение | 5 Years Чтобы 5 Years |
| Полы, имеющие право на обучение | All |
| Принимает здоровых добровольцев | да |
| Критерии | Inclusion Criteria: 1. Children of both genders aged 5 to 17 years. 2. Children with grass pollen-induced allergic rhinitis recognized and treated according to current ARIA (Allergic Rhinitis and its Impact on Asthma) recommendations. 3. Positive skin prick test to grass pollen allergens or positive specific IgE (defined as ≥ class 2, ≥ 0,70 kU/l) against timothy grass pollen allergens. 4. Presentation of clinical symptoms of the allergic rhinitis (rhinorrhea, nasal congestion, nasal itching, sneezing) in at least two recent grass pollen seasons in Poland before inclusion in the study. 5. Proper use of PMBL sublingual tablets. 6. Written informed consent obtained from parents/guardians before any study related procedures are performed. Exclusion Criteria: 1. Patient received mechanical or any other polyvalent bacterial lysate immunostimulation within the previous 12 months before visit 1. 2. Patient received oral/subcutaneous allergen-immunotherapy within the previous 3 years before the start of the study. 3. Vaccination performed within 3 months before the beginning of the study. 4. Deficiencies in cellular and humoral immunity. 5. Treatment with systemic corticosteroids within the last 6 months before the start of the study. 6. Pregnant or breastfeeding woman. 7. Other chronic conditions of the nose or nasal sinuses. |
Результат
Основные показатели результатов
1. Change in the severity of nasal SAR symptoms as assessed by Total Nasal Symptom Score (TNSS) [at baseline, at 1-month, at 2-months and at 3-months]
2. Change in the severity of ocular SAR symptoms as assessed by Total Ocular Symptom Score (TOSS) [at baseline, at 1-month, at 2-months and at 3-months]
3. Change in the nasal obstruction using Peak Nasal Inspiratory Flow (PNIF) [at baseline, at 2-months and at 3-months]
4. Change in the severity of nasal SAR symptoms as assessed by Visual Analogue Scale (VAS) [at baseline, at 2-months and at 3-months]
5. Change in the severity of ocular SAR symptoms as assessed by Visual Analogue Scale (VAS) [at baseline, at 2-months and at 3-months]
Меры вторичного результата
1. Nasal eosinophil count [at baseline, at 2-months and at 3-months]
2. Specific immunoglobulin E concentration [at baseline, at 2-months and at 3-months]
3. Frequency of oral H1-antihistamines use [from baseline, up to the 3-month time point]
4. Frequency of intranasal corticosteroids use [from baseline, up to the 3-month time point]
5. Incidence of treatment emergent adverse events [safety and tolerability] [from baseline, up to the 3-month time point]
6. Incidence of treatment emergent adverse events leading to discontinuation [safety and tolerability] [from baseline, up to the 3-month time point]
7. Time to discontinuation due to treatment emergent adverse events [safety and tolerability] [From date of randomization until the date of occurrence of an adverse event leading to discontinuation, assessed up to 3 months]
8. Incidence of treatment emergent clinical laboratory test abnormalities [safety and tolerability] [at baseline and at 3-months]
9. Incidence of treatment emergent abnormalities in physical examination findings [safety and tolerability] [at baseline, at 2-months and at 3-months]
10. Incidence of treatment emergent abnormalities in pulse rate [safety and tolerability] [at baseline, at 2-months and at 3-months]
11. Incidence of treatment emergent abnormalities in blood pressure [safety and tolerability] [at baseline, at 2-months and at 3-months]
